| Systematic (IUPAC) name | |
|---|---|
| N-[2-(4-pyrimidin-2-ylpiperazin-1-yl)ethyl]adamantane-1-carboxamide | |
| Clinical data | |
| Pregnancy cat. | ? |
| Legal status | ? |
| Identifiers | |
| CAS number | 127266-56-2 |
| ATC code | None |
| PubChem | CID 130918 |
| ChemSpider | 115774 |
| UNII | W5U6WQM26H |
| Chemical data | |
| Formula | C21H31N5O |
| Mol. mass | 369.50 g/mol |
| SMILES | eMolecules & PubChem |
|
|
| |
|
Adatanserin (WY-50,324, SEB-324) is a mixed 5-HT1A receptor partial agonist and 5-HT2A and 5-HT2C receptor antagonist.[1][2][3] It was under development by Wyeth as an antidepressant but was ultimately shelved.[3][4]
Adantaserin has been shown to be neuroprotective against ischemia-induced glutamatergic excitotoxicity, an effect which appears to be mediated by blockade of the 5-HT2A receptor.[5]
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)